Valuation: Atara Biotherapeutics, Inc.

Market Cap 96.86M 86.46M 80.36M 73.09M 138M 9.17B 140M 965M 378M 4.79B 364M 356M 15.32B P/E 2026 *
-9.75x
P/E 2027 * 8.13x
Enterprise Value 96.86M 86.46M 80.36M 73.09M 138M 9.17B 140M 965M 378M 4.79B 364M 356M 15.32B EV / Sales 2026 *
34x
EV / Sales 2027 * 2.37x
Free-Float
83.2%
Yield 2026 *
-
Yield 2027 * -
1 day+0.94%
1 week+4.55%
Current month+13.53%
1 month+2.22%
3 months+12.87%
6 months+84.16%
Current year-46.66%
1 week 8.8
Extreme 8.8
9.99
1 month 7.83
Extreme 7.83
10.28
Current year 3.92
Extreme 3.92
19.14
1 year 3.92
Extreme 3.92
19.14
3 years 3.92
Extreme 3.92
40.92
5 years 3.92
Extreme 3.92
501
10 years 3.92
Extreme 3.92
1,361.25
Manager TitleAgeSince
Chief Executive Officer 53 2024-09-08
Director of Finance/CFO 61 2026-06-25
Investor Relations Contact - 2023-06-30
Director TitleAgeSince
Director/Board Member 62 2014-02-28
Director/Board Member 66 2015-11-22
Director/Board Member 53 2024-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 Buy

Director

104,166 1.0377%
8/17/26 Sell

Chief Executive Officer

-5,062 0.0562%
7/22/26
Redmile Group LLC
ExerciceCompany 390,482 4.3338%
Change 5-day change 1-year change 3-year change Capi.($)
+0.94%+4.55%-36.85%-74.94% 96.86M
+0.21%-4.63%+55.34%+71.32% 68.98B
+0.03%+4.17%+6.69%+61.45% 53.15B
-0.05%+5.49%+10.11%+41.66% 50.83B
+3.45%+4.70%+33.44%+35.96% 44.61B
-2.20%+0.61%+281.88%+532.76% 40.57B
+6.43%+6.84%+18.32%+109.23% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
+1.74%-2.02%-13.55%-12.92% 22.66B
Average +1.09%+1.86%+39.85%+80.80% 37.98B
Weighted average by Cap. +1.07%+2.33%+50.67%+103.26%

Financials

2026 *2027 *
Net sales 2.85M 2.54M 2.36M 2.15M 4.04M 270M 4.12M 28.39M 11.11M 141M 10.69M 10.46M 450M 40.87M 36.48M 33.9M 30.84M 58.02M 3.87B 59.06M 407M 159M 2.02B 153M 150M 6.46B
Net income -14.62M -13.05M -12.13M -11.03M -20.76M -1.38B -21.13M -146M -57M -723M -54.87M -53.7M -2.31B 18.66M 16.65M 15.48M 14.08M 26.49M 1.77B 26.96M 186M 72.74M 922M 70.01M 68.53M 2.95B
Net Debt - -
Projected Income Statement - Annual - Atara Biotherapeutics, Inc.
Logo Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Employees
10
Date Price Change Volume
26-10-15 US$9.650 +0.94% 24,451
26-10-14 US$9.560 +2.74% 39,955
26-10-13 US$9.305 -0.80% 32,286
26-10-12 US$9.380 -1.05% 26,836
26-10-09 US$9.480 +2.71% 22,148
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Atara Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.650USD
Average target price
13.67USD
Spread / Average Target
+41.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Atara Biotherapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATRA Stock